Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Study objective: To investigate the potential anti-proteinuric efficacy of aliskiren, a novel
direct renin inhibitor (DRI), in addition to angiotensin receptor blocker (ARB) in
immunoglobulin A nephropathy (IgAN) patients at risk of developing progressive renal failure.
Phase:
Phase 4
Details
Lead Sponsor:
The University of Hong Kong
Collaborators:
Queen Mary Hospital, Hong Kong United Christian Hospital